An investigational mKRAS-VAX vaccine induced durable T-cell responses in 18 of 20 high-risk participants during a first-in-human study, Nature reported.
The trial targeted individuals with a hereditary predisposition to pancreatic ductal adenocarcinoma (PDAC) who also presented with radiographic pancreatic abnormalities. The study showed the pooled mutant KRAS peptide vaccine could generate immune responses, but researchers said the trial was not designed to establish whether the treatment prevents invasive cancer.
The vaccine, administered at weeks 1, 3, 5, and 13, showed a favorable safety profile. MedNet reported that all treatment-related adverse events were limited to grades 1 and 2.
A recent study published in Cancer Discovery, conducted by Haldar and colleagues, provided the first-in-human evaluation of a pooled mutant Kirsten rat sarcoma viral oncogene homolog (KRAS) peptide vaccine in individuals at high risk for PDAC. The Haldar study included a total of 20 individuals. The participants, who possessed a hereditary predisposition to PDAC and exhibited radiographic pancreatic abnormalities, received the mKRAS-VAX vaccine according to a schedule of weeks 1, 3, 5, and 13.
The vaccination induced broad and durable mutant KRAS-specific T-cell responses in most of the participants. According to the findings, 18 of the 20 participants met the prespecified criterion for immune response. Longitudinal analyses performed on a subset of the participants showed that these vaccine-induced KRAS-reactive T-cell clonotypes could persist for a duration of up to 2 years.
Participants showed a median 18.2-fold increase in pooled mutant KRAS-specific T-cell responses. However, the level of immunogenicity differed notably depending on the specific KRAS mutation variant. Nature highlighted an apparent paradox: the G12D mutation, which is the most prevalent allele in PDAC, produced the weakest immune response.
Researchers have proposed that this lower immune visibility might allow certain clones to escape natural immunosurveillance and undergo evolutionary enrichment. This hypothesis suggests that better-recognized clones may face stronger immune-mediated negative selection, while poorly recognized variants like G12D more readily persist and expand. Understanding this relationship is considered important for both the development of preventive vaccines and for the study of the evolutionary biology of KRAS-mutant PDAC.
| KRAS Mutation Variant | Median Fold Increase in T-cell Response |
|---|---|
| G12A | 43.9-fold |
| G12V | 33.7-fold |
| G12R | 21.8-fold |
| G12D | 8.3-fold |
The importance of the Haldar study lies in the timing of the vaccination attempt, providing a proof of concept for targeting oncogenic driver mutations before invasive pancreatic cancer develops. To provide broader clinical context, researchers noted observations in other cancer types.
In cases of untreated advanced melanoma, the combination of pembrolizumab with an immune-modulatory peptide vaccine designed to target PD-L1 and IDO resulted in a numerical prolongation of progression-free survival, though the results did not reach the prespecified threshold for significance. Among patients who had not previously received anti-PD-1 therapy, the median progression-free survival was 24.8 months compared to 11.0 months (HR 0.74, 95% CI 0.56–0.98).
The ability of vaccine-induced T-cell clonotypes to persist was observed for up to two years in a subset of the participants. Because KRAS mutations arise early in the development of pancreatic carcinogenesis and are present in precursor lesions such as pancreatic intraepithelial neoplasia (PanIN), researchers are investigating whether vaccination can intercept the disease before it becomes invasive.
To bridge the gap between circulating immune responses and biological effects in precancerous tissue, a window-of-opportunity cohort has been initiated. This cohort involves patients undergoing resection of high-risk pancreatic lesions, allowing researchers to study how vaccine-induced immunity interacts directly with pancreatic tissue, Nature noted.
Patients interested in the implications of pancreatic cancer research or clinical trial participation should consult with qualified medical professionals.